X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES STRIDES SHASUN LTD VENUS REMEDIES/
STRIDES SHASUN LTD
 
P/E (TTM) x -836.1 15.2 - View Chart
P/BV x 0.2 1.8 13.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   STRIDES SHASUN LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
STRIDES SHASUN LTD
Mar-17
VENUS REMEDIES/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs2181,275 17.1%   
Low Rs82918 8.9%   
Sales per share (Unadj.) Rs365.6389.6 93.9%  
Earnings per share (Unadj.) Rs1.528.0 5.3%  
Cash flow per share (Unadj.) Rs37.948.9 77.5%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs382.5303.1 126.2%  
Shares outstanding (eoy) m11.4489.42 12.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.8 14.6%   
Avg P/E ratio x101.039.2 257.6%  
P/CF ratio (eoy) x4.022.4 17.6%  
Price / Book Value ratio x0.43.6 10.8%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m1,71798,036 1.8%   
No. of employees `0001.05.8 17.6%   
Total wages/salary Rs m3245,881 5.5%   
Avg. sales/employee Rs Th4,100.76,005.9 68.3%   
Avg. wages/employee Rs Th318.01,014.0 31.4%   
Avg. net profit/employee Rs Th16.7431.2 3.9%   
INCOME DATA
Net Sales Rs m4,18334,834 12.0%  
Other income Rs m201,686 1.2%   
Total revenues Rs m4,20336,520 11.5%   
Gross profit Rs m8126,428 12.6%  
Depreciation Rs m4171,872 22.3%   
Interest Rs m3802,269 16.7%   
Profit before tax Rs m353,973 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m18470 3.9%   
Profit after tax Rs m172,501 0.7%  
Gross profit margin %19.418.5 105.2%  
Effective tax rate %51.611.8 435.9%   
Net profit margin %0.47.2 5.7%  
BALANCE SHEET DATA
Current assets Rs m2,77138,165 7.3%   
Current liabilities Rs m1,93130,402 6.4%   
Net working cap to sales %20.122.3 90.0%  
Current ratio x1.41.3 114.3%  
Inventory Days Days12577 161.7%  
Debtors Days Days54104 51.4%  
Net fixed assets Rs m5,32837,639 14.2%   
Share capital Rs m114894 12.8%   
"Free" reserves Rs m4,17726,210 15.9%   
Net worth Rs m4,37627,105 16.1%   
Long term debt Rs m1,91116,377 11.7%   
Total assets Rs m8,42881,168 10.4%  
Interest coverage x1.12.8 39.7%   
Debt to equity ratio x0.40.6 72.3%  
Sales to assets ratio x0.50.4 115.6%   
Return on assets %4.75.9 80.1%  
Return on equity %0.49.2 4.2%  
Return on capital %6.612.1 54.8%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m013,465 0.0%   
Fx outflow Rs m8584,076 21.1%   
Net fx Rs m-8589,389 -9.1%   
CASH FLOW
From Operations Rs m4692,881 16.3%  
From Investments Rs m29-7,051 -0.4%  
From Financial Activity Rs m-4643,382 -13.7%  
Net Cashflow Rs m35-788 -4.4%  

Share Holding

Indian Promoters % 32.9 27.7 118.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 37.8 0.5%  
FIIs % 0.6 8.6 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 25.9 256.4%  
Shareholders   20,121 56,241 35.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS